Comparison of Renal Function before and after Autologous Stem Cell Transplantation in Egyptian Patients with Multiple Myeloma and Renal Insufficiency: A Retrospective Study.
Humans
Multiple Myeloma
/ complications
Male
Female
Middle Aged
Egypt
Retrospective Studies
Transplantation, Autologous
Glomerular Filtration Rate
Renal Insufficiency
/ therapy
Adult
Kidney
/ physiopathology
Treatment Outcome
Hematopoietic Stem Cell Transplantation
/ adverse effects
Aged
Creatinine
/ blood
Recovery of Function
Time Factors
Renal Dialysis
Journal
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
ISSN: 1319-2442
Titre abrégé: Saudi J Kidney Dis Transpl
Pays: Saudi Arabia
ID NLM: 9436968
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
ppublish
Résumé
Renal failure is a common feature of multiple myeloma (MM) that occurs in 20%-40% of newly diagnosed patients with MM and is the result of monoclonal immunoglobulin light chains. Many studies have examined the effect of autologous stem cell transplantation (ASCT) in MM patients with renal impairment and the safety of performing the transplantation in patients with renal failure. This study aimed to compare renal function before and after ASCT in Egyptian MM patients with renal insufficiency to evaluate the effect of ASCT on renal recovery. Our study included 31 MM patients with renal impairment out of 400 patients who met the criteria of the International Myeloma Working Group for symptomatic MM. The estimated glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease formula was compared before and after the transplant. Only four patients (12.9%) were dependent on dialysis. Six of those with a history of hemodialysis (HD) who were either dependent on dialysis or dialyzed according to need achieved independence from HD. There was no significant correlation between the degree of renal impairment and the disease's status at the time of transplantation (P = 0.86). The study showed significant improvements in serum creatinine levels compared with its value before the transplant (P = 0.016) and in eGFR (P = 0.004). In total, 45% of patients achieved renal improvement, shown by a 25% increase in GFR above the baseline. There was a significant improvement of renal function after ASCT in MM patients with renal impairment.
Identifiants
pubmed: 38995270
doi: 10.4103/sjkdt.sjkdt_333_22
pii: 00936703-202307001-00003
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
S14-S23Informations de copyright
Copyright © 2023 Copyright: © 2023 Saudi Journal of Kidney Diseases and Transplantation.
Références
Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev 2018;70:199-208.
Hu J, Hu WX. Targeting signaling pathways in multiple myeloma: Pathogenesis and impli-cation for treatments. Cancer Lett 2018;414:214-21.
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
Li AY, Atenafu EG, Bernard RS, et al. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: An institutional comparison between two eras. Bone Marrow Transplant 2020;55:578-85.
Singh A, Gupta K, Chander R, et al. Sonographic grading of renal cortical echogenicity and raised serum creatinine in patients with chronic kidney disease. J Evol Med Dent Sci 2016;5:2279-86.
Chan YH. Biostatistics 102: Quantitative data - Parametric & non-parametric tests. Blood Press 2003;140:79.
7 Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic myeloma study group. Eur J Haematol 2000;65:175-81.
Tosi P, Zamagni E, Ronconi S, et al. Safety of autologous hematopoietic stem cell trans-plantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000;14:1310-3.
Parikh GC, Amjad AI, Saliba RM, et al. Autologous hematopoietic stem cell trans-plantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:812-6.
Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemo-therapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: A British society of blood and marrow transplantation study. Br J Haematol 2006;134:385-90.
St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015;50:95-9.
Mahindra A, Hari P, Fraser R, et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysis. Bone Marrow Transplant 2017;52:1616-22.
Min CK, Park SS, Min GJ, et al. Impact of autologous stem cell transplantation on renal response in multiple myeloma patients with advancedrenal failure. Clin Lymphoma Myeloma Leuk 2019;19:e216-7.
Sahin DG, Akay OM, Andic N, Teke HU, Gunduz E. Retrospective analysis of autologous stem cell transplantation outcomes in multiple myeloma patients with renal insufficiency. Ann Med Res 2021;28:1435-9.
Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell trans-plantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39:605-11.
Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol 2017;177:221-5.
Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823-8.
Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure. Eur J Haematol 2005;75:27-33.
San Miguel JF, Lahuerta JJ, García-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplan-tation? Hematol J 2000;1:28-36.
Abudayyeh A, Lin H, Mamlouk O, et al. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma 2020;61:3101-11.
Scheid C, Sonneveld P, Schmidt-Wolf IG, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014;99:148-54.
Areethamsirikul N, Masih-Khan E, Chu CM, et al. CyBorD induction therapy in clinical practice. Bone Marrow Transplant 2015;50:375-9.
Roussel M, Hebraud B, Lauwers-Cances V, et al. Bortezomib and high-dosemelphalan versus high-dose melphalan as conditioning regimen beforeautologous stem cell transplantation in de novo multiple myelomapatients: A phase 3 study of the intergroupe francophone Du myelome (IFM 2014-02). Blood 2017;130:398.
Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: An open-label, randomised, phase 3 trial. Lancet Haematol 2019;6:e266-75.
Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895-905.
McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. J Clin Oncol 2017;35:3279-89.
Gay F, Jackson G, Rosiñol L, et al. Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis. JAMA Oncol 2018;4:1389-97.
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.